This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

(Stroke. 2003;34:e61.)
© 2003 American Heart Association, Inc.

Major Ongoing Stroke Trials

An extract of the first 250 words of the full text is provided, because this article has no abstract.

African American Antiplatelet Stroke Prevention Study (AAASPS)

AAASPS is a randomized, double-blind, multicenter, controlled clinical trial to compare the effect of ticlopidine (500 mg/day) and aspirin (650 mg/day) in the prevention of recurrent stroke, myocardial infarction, and vascular death in African Americans with recent, noncardioembolic ischemic stroke. Eighteen hundred patients (900 in each group) at 50 sites nationally will be randomized at least 7 days but no more than 90 days after the qualifying event. Study patients will be followed up for 2 years. Analysis of key end points will use the intention-to-treat principle, and time-to-event data will be analyzed using Mantel-Haenszel and various regression methods. Safety analyses will focus on the incidence of severe adverse events, such as neutropenia, thrombocytopenia, gastrointestinal bleeding, and hepatic dysfunction.

Principal Investigator: Philip B. Gorelick, MD, MPH

Contact: Yvonne Harris, MPA, Center for Stroke Research, Rush Medical Center, 1645 West Jackson, Suite 400, Chicago, IL 60612. Phone 312-432-5200. Fax 312-432-0937. E-mail yharris@rush.edu

Location: Clinical Management Center and Data Management Center, Rush Medical Center, Chicago, IL

Number of Centers: 50 (recruitment is estimated to continue through September 2001)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institutes of Health (study medication supplied by Roche Laboratories and the Bayer Company)

Dates of Study: Randomization and follow-up December 15, 1995, through September 2003

Anticoagulants Versus Aspirin and the Combination of Aspirin and Dipyridamole Versus Aspirin Only in Patients With Transient Ischemic Attacks or Nondisabling Ischemic Stroke: ESPRIT (European/Australian Stroke Prevention in Reversible Ischemia Trial)

The Dutch TIA Trial and a literature review indicate that low-dose aspirin in any daily dose of at least 30 mg up to 325 mg is effective in the prevention of threatened stroke, but 87% of subsequent strokes in patients . . . [Full Text of this Article]

This article has been cited by other articles:

				M Arnold, K Nedeltchev, L Remonda, U Fischer, C Brekenfeld, B Keserue, G Schroth, and H P Mattle Recanalisation of middle cerebral artery occlusion after intra-arterial thrombolysis: different recanalisation grading systems and clinical functional outcome J. Neurol. Neurosurg. Psychiatry, October 1, 2005; 76(10): 1373 - 1376. [Abstract] [Full Text] [PDF]